Unilever is weighing a bid for U.S. supplement maker Thorne, valued at roughly $4bn. The move follows the British consumer‑goods giant’s recent spin‑off of its food division, a step designed to tighten focus on health‑and‑wellness brands. Adding a premium nutraceutical player would broaden Unilever’s portfolio beyond its traditional personal‑care and beauty lines. The proposal, still confidential, would be funded largely by cash reserves.

Unilever shed its ice‑cream and other food assets earlier this year, freeing cash and sharpening its brand architecture. Thorne brings a strong foothold in the fast‑growing supplement market, especially in the United States where preventive health spending is rising. Integration would give Unilever access to Thorne’s pipeline and delivery tech. The acquisition could lift margins, as Thorne’s products command higher price points than typical FMCG items.

Analysts note that financing a $4bn transaction may add leverage, but the potential revenue diversification could offset the risk. Competitors such as Nestlé and PepsiCo are also expanding into wellness, intensifying market pressure. With likely regulatory clearance, a completed deal would rebrand Unilever as a consumer‑health conglomerate rather than a pure beauty and home‑care group. The deal could accelerate Unilever’s initiatives, leveraging data from Thorne’s platform.